Crandell Keith's Form 4 filing
Neumora Therapeutics, Inc. (NMRA) · filed Nov 7, 2023
- Accession no.
- 0001062993-23-020279
- Filed
- Nov 7, 2023, 6:59 PM ET
- Trade date
- Nov 3-7, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $1.10M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crandell KeithCIK 0001219039 | 10% Owner |
| Nelsen RobertCIK 0001219042 | 10% Owner |
| Gillis StevenCIK 0001229592 | 10% Owner |
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 10% Owner |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 10% Owner |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +22,420 | $11.38F1 | +$255,139.6 | 3,882,318 | Indirect | Duplicate filing |
| Nov 6, 2023 | Common Stock | PPurchaseAcquired | +43,082 | $11.55F2 | +$497,597.1 | 3,925,400 | Indirect | Duplicate filing |
| Nov 7, 2023 | Common Stock | PPurchaseAcquired | +30,192 | $11.50F3 | +$347,208 | 3,955,592 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 is filed jointly by ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of common stock and is filing her own Form 4 separately.